🎉 M&A multiples are live!
Check it out!

R&G PharmaStudies Valuation Multiples

Discover revenue and EBITDA valuation multiples for R&G PharmaStudies and similar public comparables like Syngene International, Biocon, and Suven Pharma.

R&G PharmaStudies Overview

About R&G PharmaStudies

R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.


Founded

2008

HQ

China
Employees

n/a

Website

rg-pharma.com

Financials

LTM Revenue $104M

LTM EBITDA $24.4M

EV

$391M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

R&G PharmaStudies Financials

R&G PharmaStudies has a last 12-month revenue of $104M and a last 12-month EBITDA of $24.4M.

In the most recent fiscal year, R&G PharmaStudies achieved revenue of $103M and an EBITDA of $27.2M.

R&G PharmaStudies expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See R&G PharmaStudies valuation multiples based on analyst estimates

R&G PharmaStudies P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $99.4M $103M XXX XXX XXX
Gross Profit $32.4M $39.5M XXX XXX XXX
Gross Margin 33% 39% XXX XXX XXX
EBITDA $30.0M $27.2M XXX XXX XXX
EBITDA Margin 30% 27% XXX XXX XXX
Net Profit $15.7M $22.4M XXX XXX XXX
Net Margin 16% 22% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

R&G PharmaStudies Stock Performance

As of April 15, 2025, R&G PharmaStudies's stock price is CNY 47 (or $6).

R&G PharmaStudies has current market cap of CNY 4.5B (or $622M), and EV of CNY 2.8B (or $391M).

See R&G PharmaStudies trading valuation data

R&G PharmaStudies Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$391M $622M XXX XXX XXX XXX $0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

R&G PharmaStudies Valuation Multiples

As of April 15, 2025, R&G PharmaStudies has market cap of $622M and EV of $391M.

R&G PharmaStudies's trades at 3.8x LTM EV/Revenue multiple, and 16.0x LTM EBITDA.

Analysts estimate R&G PharmaStudies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for R&G PharmaStudies and 10K+ public comps

R&G PharmaStudies Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $391M XXX XXX XXX
EV/Revenue 3.8x XXX XXX XXX
EV/EBITDA 14.4x XXX XXX XXX
P/E 32.2x XXX XXX XXX
P/E/Growth 3.4x XXX XXX XXX
EV/FCF 21.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get R&G PharmaStudies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

R&G PharmaStudies Valuation Multiples

R&G PharmaStudies's NTM/LTM revenue growth is 5%

R&G PharmaStudies's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, R&G PharmaStudies's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate R&G PharmaStudies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for R&G PharmaStudies and other 10K+ public comps

R&G PharmaStudies Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 3% XXX XXX XXX XXX
EBITDA Margin 27% XXX XXX XXX XXX
EBITDA Growth -9% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 32% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 7% XXX XXX XXX XXX
R&D Expenses to Revenue 8% XXX XXX XXX XXX
Opex to Revenue 20% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

R&G PharmaStudies Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

R&G PharmaStudies M&A and Investment Activity

R&G PharmaStudies acquired  XXX companies to date.

Last acquisition by R&G PharmaStudies was  XXXXXXXX, XXXXX XXXXX XXXXXX . R&G PharmaStudies acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by R&G PharmaStudies

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About R&G PharmaStudies

When was R&G PharmaStudies founded? R&G PharmaStudies was founded in 2008.
Where is R&G PharmaStudies headquartered? R&G PharmaStudies is headquartered in China.
Is R&G PharmaStudies publicy listed? Yes, R&G PharmaStudies is a public company listed on SHE.
What is the stock symbol of R&G PharmaStudies? R&G PharmaStudies trades under 301333 ticker.
When did R&G PharmaStudies go public? R&G PharmaStudies went public in 2022.
Who are competitors of R&G PharmaStudies? Similar companies to R&G PharmaStudies include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of R&G PharmaStudies? R&G PharmaStudies's current market cap is $622M
What is the current revenue of R&G PharmaStudies? R&G PharmaStudies's last 12-month revenue is $104M.
What is the current EBITDA of R&G PharmaStudies? R&G PharmaStudies's last 12-month EBITDA is $24.4M.
What is the current EV/Revenue multiple of R&G PharmaStudies? Current revenue multiple of R&G PharmaStudies is 3.8x.
What is the current EV/EBITDA multiple of R&G PharmaStudies? Current EBITDA multiple of R&G PharmaStudies is 16.0x.
What is the current revenue growth of R&G PharmaStudies? R&G PharmaStudies revenue growth between 2023 and 2024 was 3%.
Is R&G PharmaStudies profitable? Yes, R&G PharmaStudies is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.